Cue Biopharma, Inc.

CUENASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
18.45 USD
↘ 0.21 (1.13%)AT CLOSE (03:59 PM EDT)
18.42
↘ 0.03 (0.16%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
18.42
↘ 0.03 (0.16%)
🔴Market: CLOSED

CUE is currently priced at $18.38. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Strong Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, CUE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Oct 26, 2026.

Open?$18.48
High?$18.85
Low?$17.89
Prev. Close?$18.66
Volume?181.7K
Avg. Volume?363.7K
VWAP?$18.36
Rel. Volume?0.50x
Bid / Ask
Bid?$14.62 × 100
Ask?$21.54 × 100
Spread?$6.92
Midpoint?$18.08
Valuation & Ratios
Market Cap?135.6M
Shares Out?7.3M
Float?6.5M
Float %?89.7%
P/E Ratio?N/A
P/B Ratio?58.68
EPS?-$22.59
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
29
Market Cap
135.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cuebiopharma.com
Listed
2018-01-02
Address
40 GUEST STREET
BOSTON, MA 02135
Phone: 617-949-2680
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
23
Short Sent.?
35
Piotroski F-Score?2/9Weak
Altman Z-Score?-30.31Distress
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?12.16%High
Short Interest?792.6K
Days to Cover?3.7
Free Float6.5M
Avg Daily Volume213.9K
Settlement Date2026-10-15
Financial Health
Current Ratio?1.25Adequate
Quick Ratio?1.25Adequate
Cash Ratio?0.82Adequate
Debt/Equity?0.42Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
58.68HIGH▾
P/S?
Peers
100
S&P
43
3.60FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.2CHEAP▾
EV/Sales?
Peers
100
S&P
58
3.16FAIR▾
Returns & Efficiency
ROE?
S&P
3
-7,104.2%WEAK▾
ROA?
S&P
3
-534.4%WEAK▾
Cash Flow & Enterprise
FCF?$-50167000
Enterprise Value?$119.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist